CDMO/RDMO

mAb Nanobody and Peptide Labeling

Monoclonal antibodies are common and useful mechanisms for targeting radionuclides in both diagnostic and therapeutic applications. MAbs have been radiolabeled with numerous gamma-, beta-, alpha-, and positron-electron-emitting radionuclides. Some radionuclides exhibit both beta and gamma emissions and, because of this utility, they may be used for both radioimmunodiagnosis and radioimmunotherapy approaches.

Peptides

In recent years, there has been a great acceleration in the development of radiolabeled small peptides for diagnostic imaging and radionuclide therapy in nuclear oncology. The use of radionuclide- and stable isotope labeled peptides enhances drug discovery and development. We can work with you on formulations to provide you the highest quality, custom-made radiolabeled peptides, suitable for clinical and medical applications.

Molecules & Chemical Entities

SpectronRx can provide you with numerous solutions for radiolabeling of molecules and chemical entities. Labeling is frequently used as a modality to monitor the location or biodistribution of a molecule. There are many applications for the specific labeling of molecules with radioactive or stable isotopes. .

Nanoparticles

Recently, nanoparticles have emerged in the medical and therapeutic industry as prime molecular recognition probes, due to their high affinity and specificity binding to their targets. We can help you customize the radiolabeled aptamer that will best suit your therapeutic needs.

Quality, Reliability & Sustainability

Not all products are made to order and readily available. Theranostics, and the demand changing as quickly as a decay scheme, requires special tooling and equipment for the task. The SpectronRx extensive in-house engineering team can turn your needed ideas into a world science reality.

SpectronRx excels for your timeline and ultimately first to market, with complete DOT testing and quality processes.

Recent Theranostic Advancements

The Trend is Increasing:

Multiple new worldwide commercial companies have been funded and launched specific for this endeavor with multiple clinical trials for multiple indications
Ac-225 worldwide needs and production are receiving critical attention from many including the U.S. Department of Energy along with the private sector.
Lu-177 has an FDA approved Radiotheranostic with several more being developed. Access to this isotope has increased tremendously.
Research focus on combining therapeutic and imaging agents , matching labeling with half live and alpha energy for better cancer treatment with fewer side effects.
New company acquisitions for Radiotheranostics are no longer in the millions, they are now in the billions.

CDMO/RDMO

Quality, Reliability & Sustainability

Recent Theranostic Advancements

Chat with the experts.

We’d love to understand your needs and help your patients.